Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations

Neuropsychopharmacology

Volumn 31, Issue 3, 2006, Pages 675-684

  Beuten, Joke ^a   Payne, Thomas J ^b   Ma, Jennie Z ^a   Li, Ming D ^a,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Association analysis; COMT; Haplotype; Nicotine dependence; SNP; Tobacco smoking

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; NICOTINE; VALINE;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ETHNOLOGY; EUROPEAN AMERICAN; FEMALE; GENDER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; MALE; NORMAL HUMAN; NUCLEAR FAMILY; NUCLEOTIDE SEQUENCE; POPULATION RESEARCH; PRIORITY JOURNAL; SAMPLING; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SUBSTANCE ABUSE;

ADULT; AFRICAN AMERICANS; ALLELES; CATECHOL O-METHYLTRANSFERASE; COHORT STUDIES; DNA; DOPAMINE; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; REWARD; SEX CHARACTERISTICS; SMOKING; TOBACCO USE DISORDER;

EID: 33244492833     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300997     Document Type: Article

References (71)

1. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE (2003). Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23: 2008-2013.
2. Ameyaw MM, Syvanen AC, Ulmanen I, Ofori-Adjei D, McLeod HL (2000). Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. Hum Mutat 16: 445-446.
3. Balfour DJ, Wright AE, Benwell ME, Birrell CE (2000). The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 113: 73-83.
4. Bamshad M, Wooding S, Salisbury BA, Stephens JC (2004). Deconstructing the relationship between genetics and race. Nat Rev Genet 5: 598-609.
5. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
6. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob III P (1999). Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291: 1196-1203.
7. Bilder RM, Volavka J, Lachman HM, Grace AA (2004). The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29: 1943-1961.
8. Boudikova B, Szumlanski C, Maidak B, Weinshilboum R (1990). Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48: 381-389.
9. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ et al (2003). The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348: 1170-1175.
10. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S et al (2004). Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75: 807-821.
11. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J et al (2005). Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 15: 393-398.
12. Corrigall WA, Franklin KB, Coen KM, Clarke PB (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berlin) 107: 285-289.
13. David SP, Johnstone E, Griffiths SE, Murphy M, Yudkin P, Mant D et al (2002). No association between functional catechol O-methyl transferase 1947A > G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics 12: 265-268.
14. DeMille MM, Kidd JR, Ruggeri V, Palmatier MA, Goldman D, Odunsi A et al (2002). Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum Genet 111: 521-537.
15. Edwards KL, Austin MA, Jarvik GP (1995). Evidence for genetic influences on smoking in adult women twins. Clin Genet 47: 236-244.
16. Enoch MA, Xu K, Ferro E, Harris CR, Goldman D (2003). Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatr Genet 13: 33-41.
17. Fernandes C, Paya-Cano JL, Sluyter F, D'Souza U, Plomin R, Schalkwyk LC (2004). Hippocampal gene expression profiling across eight mouse inbred strains: towards understanding the molecular basis for behaviour. Eur J Neurosci 19: 2576-2582.
18. Frisch A, Laufer N, Danziger Y, Michaelovsky E, Leor S, Carel C et al (2001). Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients. Mol Psychiatry 6: 243-245.
19. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al (2002). The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
20. Garris PA, Collins LB, Jones SR, Wightman RM (1993). Evoked extracellular dopamine in vivo in the medial prefrontal cortex. J Neurochem 61: 637-647.
21. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al (1998). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95: 9991-9996.
22. Goodman JE, Jensen LT, He P, Yager JD (2002). Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 12: 517-528.
23. Grossman MH, Emanuel BS, Budarf ML (1992). Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 12: 822-825.
24. Hatchell PC, Collins AC (1980). The influence of genotype and sex on behavioral sensitivity to nicotine in mice. Psychopharmacology (Berlin) 71: 45-49.
25. Heath AC, Kirk KM, Meyer JM, Martin NG (1999). Genetic and social determinants of initiation and age at onset of smoking in Australian twins. Behav Genet 29: 395-407.
26. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991). The Fagerstrom Test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86: 1119-1127.
27. Holmes A (2001). Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Biobehav Rev 25: 261-273.
28. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H et al (2000). Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 96: 599-603.
29. Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, Laird NM (2004). Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol 26: 61-69.
30. Kalivas PW (1993). Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 18: 75-113.
31. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J et al (1997). Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA 94: 4572-4575.
32. Kauhanen J, Hallikainen T, Tuomainen TP, Koulu M, Karvonen MK, Salonen JT et al (2000). Association between the functional polymorphism of catechol-O-methyltransferase gene and alcohol consumption among social drinkers. Alcohol Clin Exp Res 24: 135-139.
33. Khromova I, Rauhala P, Zolotov N, Mannisto PT (1995). Tolcapone, an inhibitor of catechol-O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert. Neuroreport 6: 1219-1222.
34. Khromova I, Voronina T, Kraineva VA, Zolotov N, Mannisto PT (1997). Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav Brain Res 86: 49-57.
35. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250.
36. Lange C, Silverman EK, Xu X, Weiss ST, Laird NM (2003). A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics 4: 195-206.
37. Lee SG, Joo Y, Kim B, Chung S, Kim HL, Lee I et al (2005). Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum Genet 116: 319-328.
38. Li MD, Cheng R, Ma JZ, Swan GE (2003). A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98: 23-31.
39. Li MD, Ma JZ, Beuten J (2004). Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 66: 382-392.
40. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I et al (1995). Kinetics of human soluble and membrane-bound catechol-O- methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34: 4202-4210.
41. Lundstrom K, Salminen M, Jalanko A, Savolainen R, Ulmanen I (1991). Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 10: 181-189.
42. Lundstrom K, Tenhunen J, Tilgmann C, Karhunen T, Panula P, Ulmanen I (1995). Cloning, expression and structure of catechol-O-methyltransferase. Biochim Biophys Acta 1251: 1-10.
43. Madden PA, Heath AC, Pedersen NL, Kaprio J, Koskenvuo MJ, Martin NG (1999). The genetics of smoking persistence in men and women: a multicultural study. Behav Genet 29: 423-431.
44. Matsumoto M, Weickert CS, Beltaifa S, Kolachana B, Chen J, Hyde TM et al (2003). Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 28: 1521-1530.
45. McGrath M, Kawachi I, Ascherio A, Colditz GA, Hunter DJ, De Vivo I (2004). Association between catechol-O-methyltransferase and phobic anxiety. Am J Psychiatry 161: 1703-1705.
46. McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D et al (2000). Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 10: 483-491.
47. McLeod HL, Fang L, Luo X, Scott EP, Evans WE (1994). Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 270: 26-29.
48. Nisell M, Nomikos GG, Svensson TH (1994). Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16: 36-44.
49. Nisell M, Nomikos GG, Svensson TH (1995). Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76: 157-162.
50. Nyholt DR (2004). A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74: 765-769.
51. O'Connell JR, Weeks DE (1998). PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 63: 259-266.
52. Palmatier MA, Kang AM, Kidd KK (1999). Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 46: 557-567.
53. Palmatier MA, Pakstis AJ, Speed W, Paschou P, Goldman D, Odunsi A et al (2004). COMT haplotypes suggest P2 promoter region relevance for schizophrenia. Mol Psychiatry 9: 859-870.
54. Pearce N, Foliaki S, Sporle A, Cunningham C (2004). Genetics, race, ethnicity, and health. Bmj 328: 1070-1072.
55. Perez-Stable EJ, Herrera B, Jacob 3rd P, Benowitz NL (1998). Nicotine metabolism and intake in black and white smokers. Jama 280: 152-156.
56. Perkins KA, Donny E, Caggiula AR (1999). Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1: 301-315.
57. Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382: 255-257.
58. Robinson SF, Marks MJ, Collins AC (1996). Inbred mouse strains vary in oral self-selection of nicotine. Psychopharmacology (Berlin) 124: 332-339.
59. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A et al (2002). A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71: 1296-1302.
60. Smolka MN, Budde H, Karow AC, Schmidt LG (2004). Neuroendocrinological and neuropsychological correlates of dopaminergic function in nicotine dependence. Psychopharmacology (Berlin) 175: 374-381.
61. Sullivan PF, Kendler KS (1999). The genetic epidemiology of smoking. Nicotine Tob Res 1(Suppl 2): S51-S57; discussion S69-70.
62. Swan GE (2003). The need for dissemination of evidence-based results from research on nicotine and tobacco. Nicotine Tob Res 5: 7-8.
63. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, Ulmanen I (1994). Genomic organization of the human catecholO-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 223: 1049-1059.
64. Tiihonen J, Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J et al (1999). Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry 4: 286-289.
65. US Department of Health and Human Services (1988). The Health Consequences of Smoking: Nicotine Addiction: A report of the Surgeon General.
66. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM (1997). High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74: 439-442.
67. Wang T, Franke P, Neidt H, Cichon S, Knapp M, Lichtermann D et al (2001). Association study of the low-activity allele of catechol-O-methyltransferase and alcoholism using a family-based approach. Mol Psychiatry 6: 109-111.
68. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al (2001). Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50: 825-844.
69. Weinshilboum RM, Otterness DM, Szumlanski CL (1999). Methylation pharmacogenetics: catechol-O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39: 19-52.
70. WHO (2005). The World Health Report 2005.
71. Xie T, Ho SL, Ramsden D (1999). Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 56: 31-38.